Get the Stockscreener App
1.42
3.65%
0.05
After Hours:
1.50
0.08
+5.63%
MAIA Biotechnology Inc stock is traded at $1.42, with a volume of 773.36K.
It is up +3.65% in the last 24 hours and down -7.19% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.37
Open:
$1.37
24h Volume:
773.36K
Relative Volume:
0.74
Market Cap:
$86.15M
Revenue:
-
Net Income/Loss:
$-22.40M
P/E Ratio:
-2.0234
EPS:
-0.7018
Net Cash Flow:
$-18.84M
1W Performance:
+14.52%
1M Performance:
-7.19%
6M Performance:
-1.39%
1Y Performance:
-9.55%
1-Day Range:
$1.37
$1.48
1-Week Range:
$1.16
$1.48
52-Week Range:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.42 | 83.12M | 0 | -22.40M | -18.84M | -0.7018 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan
EPS Watch: How do insiders feel about MAIA Biotechnology IncMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Aug Drivers: How does MAIA Biotechnology Inc compare to its peersMarket Risk Summary & Real-Time Sentiment Analysis - baoquankhu1.vn
Value Recap: Is MAIA Biotechnology Inc trading at a discountLayoff News & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Short Covering: Is MAIA Biotechnology Inc stock forming a cup and handle2026 Sector Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Earnings Report: Is MAIA Biotechnology Inc stock forming a cup and handle - baoquankhu1.vn
Day Trade: What are the future prospects of MAIA Biotechnology IncBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
Earnings Recap: Is MAIA Biotechnology Inc in a long term uptrend2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MAIA Biotechnology Raises $33M to Fully Fund Pivotal Phase 3 Trial of Ateganosine for Advanced NSCLC Treatment - Minichart
MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial - TipRanks
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - The Manila Times
MAIA Biotechnology says $33M raise should fully fund pivotal Phase 3 trial of ateganosine - TradingView — Track All Markets
MAIA (NYSE: MAIA) uses $33M raise to fund Phase 3 lung cancer study - Stock Titan
$33M gives MAIA runway to finish late-stage lung cancer study - Stock Titan
MAIA Biotechnology (NYSE American: MAIA) plans 2026 virtual shareholder meeting, pay vote - Stock Titan
MAIA Biotechnology Awards Executive Bonuses After Successful Financing - TipRanks
MAIA Biotechnology (NASDAQ: MAIA) director receives 27,258 stock options at $1.40 - Stock Titan
MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40 - Stock Titan
MAIA (MAIA) director receives grant of 27,258 stock options - Stock Titan
MAIA Biotechnology (MAIA) director granted 33,748 stock options - Stock Titan
MAIA (MAIA) director receives 28,556 stock options at $1.40 strike - Stock Titan
MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise - Stock Titan
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Bond Watch: How does MAIA Biotechnology Inc compare to its peersEarnings Recap Report & Growth-Oriented Investment Plans - baoquankhu1.vn
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes - TipRanks
Treasury Yields: Is now the right time to enter MAIA Biotechnology Inc2026 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
MAIA Biotechnology reports >2-year overall survival for 8 NSCLC patients in Phase 2 THIO-101 - TradingView — Track All Markets
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - The Manila Times
Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer - TradingView
Eight MAIA (NYSE: MAIA) NSCLC patients top two-year survival on Phase 2 regimen - Stock Titan
After prior treatment failed, 8 lung cancer patients lived past 2 years - Stock Titan
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 26.2% - MarketBeat
MAIA PE Ratio & Valuation, Is MAIA Overvalued - Intellectia AI
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026 - The Globe and Mail
MAIA Biotechnology presents THIO-101 poster showing sustained responses in relapsed NSCLC - TradingView
MAIA Biotechnology (NYSE American: MAIA) presents ELCC 2026 trial poster - Stock Titan
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - finance.yahoo.com
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
MAIA Biotechnology, Inc. 2025 Annual 10-K SEC Filing Overview: Private Placements, Warrants, and Equity Transactions - Minichart
MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS - marketbeat.com
MAIA Biotechnology 10-K: Operating loss $24.27M, Net loss $22.40M; Cash $8.66M - TradingView
MAIA: Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones - TradingView
MAIA Biotechnology (MAIA) advances ateganosine with Fast Track and Phase 3 NSCLC trial - Stock Titan
Market Review: Will MAIA Biotechnology Inc outperform small cap indexes2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Fundamentals Check: What are the future prospects of MAIA Biotechnology IncPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Expands By 17.9% - MarketBeat
MAIA Biotechnology (MAIA) Expected to Announce Quarterly Earnings on Friday - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 0.7%Still a Buy? - MarketBeat
MAIA Earnings History & Surprises | EPS & Revenue Results | MAIA BIOTECHNOLOGY INC (NYSEARCA:MAIA) - ChartMill
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Cap:
|
Volume (24h):